CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Current Liabilities History
[Consolidated]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|---|---|
Total Current Liabilities | ₹5,484 Cr | ₹5,246 Cr | ₹5,033 Cr | ₹4,913 Cr | ₹4,591 Cr |
What is the latest Total Current Liabilities ratio of CIPLA ?
Year | Total Current Liabilities |
---|---|
Mar2025 | ₹5,484 Cr |
Mar2024 | ₹5,246 Cr |
Mar2023 | ₹5,033 Cr |
Mar2022 | ₹4,913 Cr |
Mar2021 | ₹4,591 Cr |
How is Total Current Liabilities of CIPLA Trending?
Years | Total Current Liabilities | % Change | |
---|---|---|---|
Mar2025 | ₹5,484 Cr | 4.54 | |
Mar2024 | ₹5,246 Cr | 4.22 | |
Mar2023 | ₹5,033 Cr | 2.45 | |
Mar2022 | ₹4,913 Cr | 7.01 | |
Mar2021 | ₹4,591 Cr | - |
Compare Total Current Liabilities of peers of CIPLA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
CIPLA | ₹124,538.5 Cr | -1.1% | -3.2% | -4.6% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹394,451.0 Cr | 2.1% | 0.3% | -9.6% | Stock Analytics | |
DIVIS LABORATORIES | ₹161,727.0 Cr | -0% | 1.1% | 13.4% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹123,673.0 Cr | 3.4% | 0.2% | 8.1% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹108,629.0 Cr | -0.7% | 2% | 0.7% | Stock Analytics | |
MANKIND PHARMA | ₹107,160.0 Cr | 1.1% | -0.2% | 11% | Stock Analytics |
CIPLA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
CIPLA | -1.1% |
-3.2% |
-4.6% |
SENSEX | 0.5% |
0.4% |
-1.1% |
You may also like the below Video Courses